What Partner Therapeutics does

Partner Therapeutics (PTx) is a privately held, integrated biopharmaceutical company founded in 2017 and headquartered in Lexington, Massachusetts, with a secondary office in Lynnwood, Washington. The company develops and commercializes late-stage therapeutics for cancer and serious diseases, and develops host-directed treatments for global health security threats. Its commercial portfolio is anchored by two FDA-approved products: BIZENGRI (zenocutuzumab-zbco), a bispecific HER2/HER3 antibody licensed from Merus N.V. (a Genmab subsidiary) that blocks NRG1 fusion-driven oncogenic signaling and is approved for NRG1 fusion-positive NSCLC, pancreatic adenocarcinoma, and cholangiocarcinoma; and LEUKINE (sargramostim), a yeast-derived recombinant human GM-CSF with multiple hematology/oncology indications and inclusion in the U.S. Strategic National Stockpile for acute radiation syndrome and pandemic preparedness.

The company monetizes BIZENGRI and LEUKINE through traditional specialty-pharma distribution channels in the U.S., a Named Patient Program administered by Tanner Pharma Group outside the U.S., and a partnership with Nobelpharma for SARGMALIN in Japan; non-dilutive revenue also flows from milestone-based government contracts with the DoD (JPEO-CBRND) and BARDA for medical countermeasure development. PTx serves three primary customer cohorts: (1) oncology patients with NRG1+ biomarker-defined solid tumors treated at major academic centers including Dana-Farber and Memorial Sloan Kettering; (2) hematology/oncology patients requiring myeloid reconstitution post-chemotherapy, transplant, or radiation exposure; and (3) federal agencies procuring Leukine for the Strategic National Stockpile and CBRN defense programs.

The business is supported by investigator-initiated research at the University of Colorado (Alzheimer's and Down syndrome) and the University of Nebraska (Parkinson's disease), alongside licensing collaborations with SIRS Therapeutics and F4 Pharma on FX-06 for capillary leak and pandemic indications. Operationally, PTx employs 101-250 staff and operates with no disclosed venture capital or institutional investor base beyond its 2018 funding round, suggesting founder/management-controlled ownership.

Name

Partner Therapeutics

Legal name

Partner Therapeutics, Inc.

Website

https://partnertx.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

Partner Therapeutics is a privately held Boston-area biopharmaceutical company that develops and commercializes BIZENGRI, a bispecific HER2/HER3 antibody for NRG1 fusion-positive cancers, and LEUKINE, a recombinant GM-CSF for hematology, oncology, and government medical countermeasure applications.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industries

Oncology & Hematology Pharmaceuticals (HLAIAAAC), Transplant & Immunosuppression Specialty Pharmaceuticals (HLAIACAJ)

Keywords

• Oncology therapeutics
• Bispecific antibodies
• Immunomodulatory drugs
• Medical countermeasures
• Hematopoietic agents

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical product sales: Revenue generated from the sale of FDA-approved prescription pharmaceuticals including BIZENGRI (zenocutuzumab-zbco) for NRG1+ cancers and LEUKINE (sargramostim) for hematopoietic/immune indications. The company commercializes drugs directly in the US market and through named-patient programs outside the US.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Partner Therapeutics develops and commercializes FDA-approved biopharmaceutical products for cancer and serious diseases. The company markets BIZENGRI (zenocutuzumab-zbco), a bispecific HER2/HER3 antibody for NRG1 fusion-positive cancers, and LEUKINE (sargramostim), a recombinant human GM-CSF for hematopoietic support and medical countermeasure applications. The company also develops host-directed therapeutic treatments for global health security threats under government contracts.

Product overview

Partner Therapeutics is an integrated biotechnology company focused on development and commercialization of late-stage therapeutics for cancer and serious diseases. The portfolio includes BIZENGRI (zenocutuzumab-zbco), a bispecific HER2/HER3 antibody targeting NRG1 fusion-positive cancers, and LEUKINE (sargramostim), a GM-CSF immunomodulator with applications in oncology, acute radiation syndrome, and global health security threats.

Differentiator

Problem solved

Functional benefit

Brands

• BIZENGRI: BIZENGRI (zenocutuzumab-zbco) is a bispecific antibody approved for NRG1 fusion-positive cancers including NSCLC, pancreatic adenocarcinoma, and cholangiocarcinoma. It is a registered trademark of Merus B.V. licensed to Partner Therapeutics for U.S. development and commercialization.
• LEUKINE
• IMREPLYS
• SARGMALIN

Products and services

• BIZENGRI (zenocutuzumab-zbco) A bispecific HER2/HER3 antibody approved by the FDA for treatment of adults with advanced unresectable or metastatic solid tumors harboring NRG1 gene fusions, including non-small cell lung cancer, pancreatic adenocarcinoma, and cholangiocarcinoma. It blocks HER2/HER3 dimerization and NRG1 fusion interactions with HER3 to suppress oncogenic signaling. Partner Therapeutics holds exclusive U.S. commercialization rights licensed from Merus N.V.
• LEUKINE (sargramostim) A yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhuGM-CSF) with immunomodulatory properties. FDA-approved for acute myeloid leukemia, bone marrow transplantation, and acute radiation syndrome. Marketed as LEUKINE in the U.S., IMREPLYS in the EU, and SARGMALIN in Japan. Held in the U.S. Strategic National Stockpile for national biodefense preparedness.

Quantifiable outcome

• 36.8% overall response rate in NRG1+ cholangiocarcinoma (95% CI: 16.3, 61.6%)
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Eight partnerships are on record, tiered minor and core.

• Cholangiocarcinoma FoundationminorOthers · 6 May 2026Patient advocacy organization supporting awareness and research for cholangiocarcinoma. CEO Stacie Lindsey quoted in support of BIZENGRI approval.
• U.S. Department of Defense (DoD) / JPEO-CBRNDcoreStrategic or Co-development Partner · 17 February 2022Milestone-based Other Transaction Agreement (OTA) with the DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense to fund development and regulatory activities for Leukine to treat sulfur mustard gas exposure. Previously awarded $39.5 million for COVID-19 studies and $35 million for advanced development and EUA request for Leukine as COVID-19 treatment.
• BARDAcoreStrategic or Co-development Partner · 20 September 2021Collaboration with Biomedical Advanced Research and Development Authority to advance a diagnostic approach for immunoparalyzed sepsis patients that could benefit from Leukine treatment. Partnership includes development of HLA-DR Laboratory Developed Test with Labcorp Drug Development.
• Labcorp Drug DevelopmentminorStrategic or Co-development Partner · 20 September 2021Collaboration with Labcorp Drug Development to develop and validate a quantitative flow cytometric Laboratory Developed Test (LDT) for HLA-DR protein on circulating monocytes to identify immunoparalyzed sepsis patients.
• SIRS TherapeuticsminorStrategic or Co-development Partner · 3 March 2021Licensing and collaboration agreement with Munich-based SIRS Therapeutics to support development of FX-06, a synthetic peptide with potential applications in COVID-19, pandemic, chemical, biological, radiological and nuclear threats.
• F4 PharmaminorStrategic or Co-development Partner · 3 March 2021Licensing and collaboration agreement with Vienna-based F4 Pharma to support FX-06 development for diseases associated with capillary leak and endothelial barrier integrity.
• Merus N.V. (Genmab subsidiary)coreOEM/ Whitelabel/ Licensing PartnerUnder an agreement with Merus, PTx has exclusive rights to develop, manufacture, and commercialize zenocutuzumab-zbco (BIZENGRI) for the treatment of NRG1+ cancer in the U.S. and provide the product on a named-patient basis outside the U.S. pending regulatory developments.
• Nobelpharma Co. LtdminorChannel Partner/ Reseller/ DistributorPartnership with Nobelpharma Co. Ltd for commercialization of SARGMALIN (sargramostim) in Japan.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Jazz Pharmaceuticals: Jazz Pharmaceuticals previously owned LEUKINE (sargramostim) and divested it to Partner Therapeutics in 2018, making it the most directly comparable peer in terms of product history, oncology/hematology commercial focus, and rare-disease commercial model.
• Merus N.V. Merus N.V. (now a Genmab subsidiary) is the originator and licensor of zenocutuzumab (BIZENGRI), operating in the same bispecific antibody oncology niche. Both companies share the same molecular asset, making this the closest direct peer in technology and target patient population.
• Genmab: Genmab acquired Merus and is a global leader in bispecific antibody technology (including approved products like Rybrevant and Tecvayli). It competes directly with PTx's BIZENGRI in oncology bispecifics while sharing the underlying antibody platform via Merus.
• MacroGenics: MacroGenics is a clinical-stage biopharmaceutical company developing bispecific antibodies and antibody-based therapeutics for cancer, sharing PTx's bispecific antibody approach to oncology and overlapping target patient populations in solid tumors.
• Incyte Corporation: Incyte is a specialty oncology and hematology company with approved products like Jakafi and a pipeline of targeted therapies, making it highly comparable in commercial stage, patient population focus (rare hematology/oncology), and specialty distribution model.
• BeiGene: BeiGene is a global oncology biotechnology company with approved products like Brukinsa and tislelizumab. It shares PTx's commercial-stage oncology focus and pursues similar strategic partnerships and global commercialization strategies.
• Bavarian Nordic: Bavarian Nordic is a biodefense-focused biotech with smallpox/mpox vaccines and government stockpile contracts. It is highly comparable to PTx's LEUKINE strategy of leveraging government contracts and Strategic National Stockpile positioning for durable revenue.
• Emergent BioSolutions: Emergent BioSolutions is a biodefense-focused company with multiple BARDA contracts and Strategic National Stockpile placements. It mirrors PTx's LEUKINE biodefense franchise with similar government countermeasure business model.

Broad incumbents

• Roche: Roche is the established leader in bispecific antibodies (Hemlibra, Vabysmo) with deep oncology and hematology portfolios. It competes with PTx in the HER2/HER3 oncology space and represents a much larger, broadly diversified incumbent.
• AstraZeneca: AstraZeneca has a major oncology franchise including bispecific antibodies (e.g., Datroway, Imfinzi) and competes broadly in NRG1, HER2/HER3, and cholangiocarcinoma markets where PTx operates, though at vastly larger scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/PartnerTx
• Facebookfacebook.com/partnertherapeutics
• LinkedInlinkedin.com/company/partner-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Partner Therapeutics